Drugs / BP1002
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05190471 | Aug 2022 → Mar 2027 expected | acute myeloid leukemia | Bio-Path Holdings, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04072458 | Nov 2020 → Apr 2025 overdue | Hodgkins lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma +5 | Bio-Path Holdings, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BP1002 | “This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies.” NCT04072458 ↗ |
| Modality | Antisense oligonucleotide | “BP1002 (L-Bcl-2) Antisense Oligonucleotide” NCT04072458 ↗ |
| Route | Intravenous | “BP1002 is given as an intravenous infusion” NCT04072458 ↗ |
| Target | BCL2 | “BP1002 (a Liposomal Bcl-2 Antisense Oligodeoxynucleotide)” NCT05190471 ↗ |